Prosensa Holding N.V. announced initial findings from further analyses from the aggregate data from the clinical development program of drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD).
“We are encouraged by these results that suggest that treating earlier in the disease and treating longer shows a delay in the progression of the disease,” said Hans Schikan, Prosensa’s chief executive officer. “These data encourage us to engage patient groups, clinical experts and regulators to explore a path forward for drisapersen, which includes the possibility of re-dosing.”
With data from more than 300 patients, Prosensa has the largest clinical data set in DMD. In order to advance the general understanding of DMD, Prosensa has also announced that it will make certain data from the drisapersen clinical program available to the scientific community. In addition it has initiated a study to better understand the natural history of DMD and is also exploring potential biomarkers that could be of use as indicators of efficacy in DMD clinical trials.
The subset analyses focus on outcomes in DMD boys seven years or younger and those over seven years old as measured by the six-minute walk test (6MWT). In all studies, a treatment difference was seen in the younger patient population.
Notably, the preliminary analysis of the 96-week extension data from those participating in the Phase 3 DMD114044 (DEMAND 3) study shows a 49-meter difference between those on continual treatment and those who had been on placebo for 48 weeks followed by active drug. Those previously participating in the DMD114117 study (DEMAND 2) showed a 52-meter difference at 96 weeks.
Key safety findings are consistent with previous observations, including injection site reactions, proteinuria and mild to severe thrombocytopenia.
Schikan concluded: “We will continue to work closely with patient groups, clinical experts and regulators to ensure that we leave no stone unturned to bring treatments to boys affected by DMD.”
Date: January 16, 2014
Filed Under: Drug Discovery